AD-35 is an orally active anti-Alzheimers disease (AD) agent with moderate AChE inhibitory activity and metal ion chelating ability. AD-35 exhibits IC50 values for AChE and BuChE of 793 nM and 31428 nM, respectively. AD-35 can form chelates with Cu and Fe, but its chelating ability for Zn is relatively weak. AD-35 can inhibit Abeta aggregation and disassemble the formed Abeta aggregates, and inhibit Abeta-induced ERK phosphorylation. AD-35 inhibits neuroinflammation in AD rat models and demonstrates a strong effect in improving cognitive function[1].
